SEC Form 4 · accession 0001213900-18-002730
Actinium Pharmaceuticals, Inc. · ATNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard I Steinhart
Director
Period of report
Mar 6, 2018
Accepted (ET)
Mar 8, 2018 · 4:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001388320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 6, 2018 | J | 7,000 | $0.50 | A | 9,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Warrants | $0.60 | Mar 6, 2018 | J | 1,750 | A | Mar 6, 2018 | Mar 6, 2019 | Common Stock | 1,750 | 1,750 | D |
| Series B Warrants | $0.70 | Mar 6, 2018 | J | 5,250 | A | Mar 6, 2018 | Sep 6, 2020 | Common Stock | 5,250 | 5,250 | D |
Remarks
J - Purchase of units on March 6. 2018 in rights offering made to common stock holders and participating warrant holders. Each unit consisted of one share of common stock, 0.25 series A warrant and 0.75 series B warrant, at a purchase price of $0.50 per unit.